ArticleProceedings of the National Academy of Sciences of the United States of America2017
Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 143 citations in OpenAlex.
- Trial
- Structural organization of TAM receptor ectodomains.The Biochemical journal · 2026Article
- A novel Tie2xVEGF bispecific antibody fusion demonstrates enhanced therapeutic efficacy through direct Tie2 activation and VEGF neutralization.Journal of translational medicine · 2026Article
- Inactive β1-integrin acts as a junctional scaffold for angiopoietin/TIE2/FOXO1 signaling.The Journal of clinical investigation · 2026Article
- TIE2-positive cells in the nucleus pulposus with a purpose: the who, what and why.Journal of biomedical science · 2026Review
- Deletion of the angiopoietin receptor Tie2 enhances proliferation and sprouting of cardiac endothelial cells.Angiogenesis · 2026Article
- Advancing Intervertebral Disc Biology via Omics: Implications for Nucleus Pulposus Progenitor Cell-Based Regeneration.JOR spine · 2025Review
- TIE1-dependent lymphatic vascular remodeling is mediated by its second tyrosine kinase domain.Development (Cambridge, England) · 2025Article
- Promoting vascular stability through Src inhibition and Tie2 activation: A model-based analysis.iScience · 2025Article
- Cathepsin K cleavage of angiopoietin-2 creates detrimental Tie2 antagonist fragments in sepsis.The Journal of clinical investigation · 2025Article
- Mechanistic studies and therapeutic potential of angiopoietin in head and neck tumor angiogenesis.Frontiers in oncology · 2025Review
- Exploring Angiopoietin-2: Clinical Insights and Experimental Perspectives in Kidney Diseases.Kidney international reports · 2024Review
- Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases.Journal of translational medicine · 2024Review
- Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2Angiogenesis · 2024Article
- Assessment of Tie2-Rejuvenated Nucleus Pulposus Cell Transplants from Young and Old Patient Sources Demonstrates That Age Still Matters.International journal of molecular sciences · 2024Article
- The mechanosensory channel PIEZO1 functions upstream of angiopoietin/TIE/FOXO1 signaling in lymphatic development.The Journal of clinical investigation · 2024Article
- Mechanisms of Sepsis-Induced Acute Lung Injury and Advancements of Natural Small Molecules in Its Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage.Molecular therapy. Nucleic acids · 2023Article
- TIE1 and TEK signalling, intraocular pressure, and primary open-angle glaucoma: a Mendelian randomization study.Journal of translational medicine · 2023Article
- The Role of Angiopoietins in Neovascular Diabetes-Related Retinal Diseases.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endothelial cell (EC)-specific receptor tyrosine kinases Tie1 and Tie2 are necessary for the remodeling and maturation of blood and lymphatic vessels. Angiopoietin-1 (Ang1) growth factor is a Tie2 agonist, whereas Ang2 functions as a context-dependent agonist/antagonist. The orphan receptor Tie1 modulates Tie2 activation, which is induced by association of angiopoietins with Tie2 in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.